<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">	
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbio.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbio.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Research Foundation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2012.00267</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Review Article</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Species tropism of HIV-1 modulated by viral accessory proteins</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Nomaguchi</surname> <given-names>Masako</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Doi</surname> <given-names>Naoya</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Matsumoto</surname> <given-names>Yui</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Sakai</surname> <given-names>Yosuke</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Fujiwara</surname> <given-names>Sachi</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Adachi</surname> <given-names>Akio</given-names></name>
<xref ref-type="author-notes" rid="fn001"><sup>&#x0002A;</sup></xref>
</contrib>
</contrib-group>
<aff><institution>Department of Microbiology, Institute of Health Biosciences, The University of Tokushima Graduate School,</institution> <country>Tokushima, Japan</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: <italic>Mikako Fujita, Kumamoto University, Japan</italic></p></fn>
<fn fn-type="edited-by"><p>Edited by: <italic>Mikako Fujita, Kumamoto University, Japan Yasuyuki Miyazaki, The University of Tokushima Graduate School, Japan</italic></p></fn>
<fn fn-type="corresp" id="fn001"><p>&#x0002A;Correspondence: <italic>Akio Adachi, Department of Microbiology, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima-shi, Tokushima 770-8503, Japan. e-mail: <email>adachi@basic.med.tokushima-u.ac.jp</email></italic></p></fn>
<fn fn-type="other" id="fn002"><p>This article was submitted to Frontiers in Virology, a specialty of Frontiers in Microbiology.</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>26</day>
<month>07</month>
<year>2012</year>
</pub-date>
<pub-date pub-type="collection">
<year>2012</year>
</pub-date>
<volume>3</volume>
<elocation-id>267</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>07</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>07</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; Nomaguchi, Doi,Matsumoto, Sakai, Fujiwara and Adachi.</copyright-statement>
<copyright-year>2012</copyright-year>
<license license-type="open-access" xlink:href="http://www.frontiersin.org/licenseagreement"><p> This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</ext-link>, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.</p></license>
</permissions>
<abstract>
<p>Human immunodeficiency virus type 1 (HIV-1) is tropic and pathogenic only for humans, and does not replicate in macaque monkeys routinely used for experimental infections. This specially narrow host range (species tropism) has impeded much the progress of HIV-1/acquired immunodeficiency syndrome (AIDS) basic research. Extensive studies on the underlying mechanism have revealed that Vif, one of viral accessory proteins, is critical for the HIV-1 species tropism in addition to Gag-capsid protein. Another auxiliary protein Vpu also has been demonstrated to affect this HIV-1 property. In this review, we focus on functional interactions of these HIV-1 proteins and species specific-restriction factors. In addition, we describe an evolutional viewpoint that is relevant to the species tropism of HIV-1 controlled by the accessory proteins.</p>
</abstract>
<kwd-group>
<kwd>HIV-1</kwd>
<kwd>species tropism</kwd>
<kwd>accessory protein</kwd>
<kwd>Vif</kwd>
<kwd>Vpu</kwd>
</kwd-group>
<counts>
<fig-count count="4"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="41"/>
<page-count count="6"/>
<word-count count="0"/>
</counts>
</article-meta>
</front>
<body>
<sec>
<title>INTRODUCTION</title>
<p>Human immunodeficiency virus type 1 (HIV-1) is strictly adapted to humans, and cause disease-inducing persistent infection only in humans (<xref ref-type="bibr" rid="B24">Nomaguchi et al., 2008</xref>). This property is unique among primate immunodeficiency viruses, and represent one of the most evident and important viral characteristics to understand the biology/molecular biology of HIV-1. Of numerous primate immunodeficiency viruses so far identified (<xref ref-type="bibr" rid="B17">Kirchhoff, 2009</xref>; <xref ref-type="bibr" rid="B31">Sharp and Hahn, 2011</xref>), HIV-1 with an extremely limited host range exhibits exceptionally high replication ability, transmissibility, and pathogenicity in sensitive host humans. For basic HIV-1 researchers, it would be final goal to realize the basis/mechanism underlying these properties by experimental approaches.</p>
<p>Primate immunodeficiency viruses can be divided into three groups based on their genome structure in the central regions (<xref ref-type="bibr" rid="B17">Kirchhoff, 2009</xref>; <xref ref-type="bibr" rid="B8">Fujita et al., 2010</xref>; <xref ref-type="bibr" rid="B31">Sharp and Hahn, 2011</xref>). While viruses of HIV-1 type contain <italic>vpr</italic> and <italic>vpu</italic> genes, viruses of HIV-2 type carry <italic>vpx</italic> and <italic>vpr</italic> genes in tandem (<bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold>). The other simian immunodeficiency viruses (SIVs), the prototype virus, have only the <italic>vpr</italic> gene in the corresponding genomic region. HIV-1 is believed to emerge from the prototype virus via SIVmon/mus/gsn (isolated from the mona, mustached, and greater spot-nosed monkeys), SIVcpz (isolated from the chimpanzees), and SIVgor (isolated from the gorilla) through mutational and recombinational events. SIVmon/mus/gsn is known to recombine with SIVrcm (isolated from the red-capped mangabey monkey) to generate SIVcpz (for genome structures, see, <bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold>). SIVcpz served as parental virus for HIV-1 (M and N) and SIVgor (and finally for HIV-1 P).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p><bold>Genome organization of primate immunodeficiency viruses.</bold> Various proviral genomes are schematically shown. As indicated by colored boxes, the <italic>vpr</italic> and <italic>vpu</italic> genes of SIVcpz/HIV-1 came from those of SIVrcm and SIVmon/mus/gsn, respectively. Also, the<italic> vif</italic> genes of SIVcpz/HIV-1 originated from that of SIVrcm. In addition, as shown by colored boxes, HIV-1 <italic>nef</italic> gene is similar to but distinct from SIVcpz <italic>nef</italic> gene. HIV-1 <italic>nef</italic> gene is different from those of SIVmon/mus/gsn, SIVrcm, and HIV-2 as indicated. For virus designations, see text.</p></caption>
<graphic xlink:href="fmicb-03-00267-g001.tif"/>
</fig>
<p>The biological and molecular biological bases for species tropism of HIV-1 should reside in the above outlined evolutional processes. In particular, the so-called accessory proteins encoded by extra genes are important. Each virus group has a unique set of the accessory proteins in terms of their combinations and of their activities. Therefore, studies on viral accessory proteins are also meaningful for understanding viral evolution by cross-species transmission.</p>
</sec>
<sec>
<title>VIRAL AND CELLULAR DETERMINANTS FOR HIV-1 SPECIES TROPISM</title>
<p>Our early studies have already suggested the possible viral determinants and viral replication stage involved in the HIV-1 species tropism described above (<xref ref-type="bibr" rid="B34">Shibata et al., 1991</xref>, <xref ref-type="bibr" rid="B35">1995</xref>; <xref ref-type="bibr" rid="B33">Shibata and Adachi, 1992</xref>). By the use of numerous chimeric molecular clones between HIV-1 and dual-tropic (tropic for human and monkey cells) SIVmac (isolated from the macaque monkey), we have claimed in essence, together with a work on the cyclophilin A (CypA; <xref ref-type="bibr" rid="B4">Dorfman and Gottlinger, 1996</xref>), that Gag-capsid (CA) and a viral protein(s) encoded by the central genomic region of HIV-1 are the determinants. We also have showed that HIV-1 is replication-incompetent in monkey cells because a certain replication step(s) before/during reverse transcription, other than the viral entry into cells, does not proceed normally. Subsequent extensive studies by us and others have clearly indicated that the interactions of Gag-CA/CypA, Gag-CA/tripartite motif (TRIM) proteins, and Vif/apolipoprotein B mRNA-editing enzyme-catalytic (APOBEC) proteins are major determinants for the HIV-1 species tropism (<xref ref-type="bibr" rid="B24">Nomaguchi et al., 2008</xref>, <xref ref-type="bibr" rid="B25">2011</xref>; <xref ref-type="bibr" rid="B22">Nakayama and Shioda, 2012</xref>; <xref ref-type="bibr" rid="B27">Sakuma and Takeuchi, 2012</xref>) as summarized in <bold>Table <xref ref-type="table" rid="T1">1</xref></bold>. Gag-CA, CypA, and TRIM proteins have been described in detail in two articles in the Research Topic of this journal (<xref ref-type="bibr" rid="B22">Nakayama and Shioda, 2012</xref>; <xref ref-type="bibr" rid="B27">Sakuma and Takeuchi, 2012</xref>).</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p> Major viral and cellular determinants for HIV-1 species tropism.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Virus</th>
<th valign="top" align="left">Cell</th>
<th valign="top" align="left">Viral replication step affected</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Gag-CA</td>
<td valign="top" align="left">CypA</td>
</tr>
<tr>
<td valign="top" align="left">Gag-CA</td>
<td valign="top" align="left">TRIM5&#x003B1;</td>
<td valign="top" align="left">Uncoating (early phase)</td>
</tr>
<tr>
<td valign="top" align="left">Gag-CA</td>
<td valign="top" align="left">TRIMCyp</td>
<td valign="top" align="left">Uncoating (early phase)</td>
</tr>
<tr>
<td valign="top" align="left">Vif</td>
<td valign="top" align="left">APOBEC3G</td>
<td valign="top" align="left">Reverse transcription (early phase)</td>
</tr>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="left">APOBEC3F</td>
<td valign="top" align="left">Reverse transcription (early phase)</td>
</tr>
<tr>
<td valign="top" align="left">Vpu</td>
<td valign="top" align="left">Tetherin/BST-2</td>
<td valign="top" align="left">Virion release (late phase)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<attrib><italic>For details, see references (<xref ref-type="bibr" rid="B22">Nakayama and Shioda, 2012</xref>; <xref ref-type="bibr" rid="B27">Sakuma and Takeuchi, 2012</xref>) for Gag-CA, and Figures <xref ref-type="fig" rid="F3">3</xref> and <xref ref-type="fig" rid="F4">4</xref> for Vif/Vpu.</italic></attrib></table-wrap-foot></table-wrap>
</sec>
<sec>
<title>ACCESSORY PROTEINS OF PRIMATE IMMUNODEFICIENCY VIRUSES</title>
<p>All primate immunodeficiency viruses encode a number of extra proteins (Vif, Vpx, Vpr, Vpu, and Nef) in addition to regulatory (Tat and Rev) and structural (Gag, Pol, and Env) proteins (<bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold>). Structural proteins are common to all retroviruses, but the regulatory and accessory proteins are unique to the complex primate lentiviruses and not found in the other simple mammalian retroviruses. Regulatory Tat and Rev proteins are trans-activators for transcription and for the expression of late viral proteins, respectively. While the regulatory and structural proteins are essential for viral replication, the extra proteins, unfairly generically called &#x0201C;accessory,&#x0201D; are dispensable under certain circumstances. However, in some cells, some of them are essential and the others are quite critical/important for optimal viral replication as illustrated for &#x00394;Vif and &#x00394;Vpu viruses (viruses that lack Vif or Vpu) in <bold>Figure <xref ref-type="fig" rid="F2">2</xref></bold>. Another point to be mentioned here is relating to Vpr/Vpx proteins. Although Vpr and Vpx are genetically very similar (<xref ref-type="bibr" rid="B16">Khamsri et al., 2006</xref>), some primate immunodeficiency viruses bear two of them as described above (<xref ref-type="bibr" rid="B8">Fujita et al., 2010</xref>). Furthermore, the other viruses have Vpr only. What about the functional relationship of the two proteins? At present, the function of Vpr/Vpx is least well understood relative to that of the other accessory proteins (<xref ref-type="bibr" rid="B21">Malim and Emerman, 2008</xref>; <xref ref-type="bibr" rid="B8">Fujita et al., 2010</xref>). <bold>Table <xref ref-type="table" rid="T2">2</xref></bold> summarizes the important information regarding these accessory proteins so far reported. In total, it is fairly reasonable to believe that the accessory proteins are regulators to optimize viral replication and persistence <italic>in vivo</italic> thereby enhancing viral transmission between individuals.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p><bold>A schema of replication kinetics by HIV-1 wild-type and mutant viruses.</bold> Viral growth properties in cells are illustrated based on numerous infection experiments in our laboratory. WT, wild-type.</p></caption>
<graphic xlink:href="fmicb-03-00267-g002.tif"/>
</fig>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p> Accessory proteins of primate immunodeficiency viruses.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Viral Proteins</th>
<th valign="top" align="left">Major functions for viral replication reported so far</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Vif</td>
<td valign="top" align="left">Neutralize APOBEC3G/F. Essential for viral replication in natural target cells.</td>
</tr>
<tr>
<td valign="top" align="left">Vpx</td>
<td valign="top" align="left">Degrade SAMHD1/APOBEC3A. Critical for viral replication in natural target cells.</td>
</tr>
<tr>
<td valign="top" align="left">Vpr</td>
<td valign="top" align="left">Important for viral replication in macrophages (HIV-1).</td>
</tr>
<tr> 
<td valign="top" align="left">Vpu</td>
<td valign="top" align="left">Down-regulate Tetherin/BST-2. Important for viral replication in CD4-positive cells.</td>
</tr>
<tr>
<td valign="top" align="left">Nef</td>
<td valign="top" align="left">Down-regulate cell surface molecules (CD4, MHC-I etc.).</td></tr></tbody></table></table-wrap>
</sec>
<sec>
<title>Vif AND Vpu PROTEINS</title>
<p>Vif protein is essential for viral replication in natural target cells such as CD4-positve lymphocytes and macrophages. Recent identification of its cellular object for attack (<xref ref-type="bibr" rid="B32">Sheehy et al., 2002</xref>) has clearly revealed the biological and biochemical bases for the growth property of &#x00394;Vif virus in natural target cells. This finding (identification of a family of APOBEC3 proteins, cellular cytidine deaminases, as potent inhibitors of HIV-1 replication in primary cells) has also contributed much to establish the concept of &#x0201C;the restriction factor&#x0201D; to well understand virus&#x02013;cell interaction (<xref ref-type="bibr" rid="B21">Malim and Emerman, 2008</xref>; <xref ref-type="bibr" rid="B28">Sato et al., 2012</xref>). Of the APOBEC3 family proteins, APOBEC3G and APOBEC3F (<xref ref-type="bibr" rid="B18">Kitamura et al., 2011</xref>) strongly inhibit viral replication in the absence of Vif (<bold>Figure <xref ref-type="fig" rid="F3">3</xref></bold>). Although HIV-1 Vif can abrogate the activities of human APOBEC3, it cannot do so against monkey APOBEC3. In contrast, SIVmac Vif can neutralize the anti-viral activity of APOBEC3 of both origins. Finally, it has been demonstrated that Vif and APOBEC3 are the major determinants for the HIV-1 species tropism by constructing macaque-tropic HIV-1 (HIV-1mt) and monitoring the HIV-1mt growth property in various genetic contexts of macaques (<xref ref-type="bibr" rid="B10">Hatziioannou et al., 2006</xref>, <xref ref-type="bibr" rid="B9">2009</xref>; <xref ref-type="bibr" rid="B15">Kamada et al., 2006</xref>; <xref ref-type="bibr" rid="B14">Igarashi et al., 2007</xref>; <xref ref-type="bibr" rid="B38">Thippeshappa et al., 2011</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p><bold>HIV-1 replication and APOBEC3G.</bold> On the basis of results reported so far, the action mechanism of Vif is depicted. Replication process for wild-type (WT) and &#x00394;Vif mutant viruses are schematically shown on the basis of previously reported review articles (<xref ref-type="bibr" rid="B11">Holmes et al., 2007</xref>; <xref ref-type="bibr" rid="B13">Huthoff and Towers, 2008</xref>; <xref ref-type="bibr" rid="B37">Strebel et al., 2009</xref>). A3G, APOBEC3G; IN, viral integrase protein.</p></caption>
<graphic xlink:href="fmicb-03-00267-g003.tif"/>
</fig>
<p>Vpu protein, unique to viruses of the HIV-1 group (<bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold>), modulates viral replication in human CD4-positive cell lines and primary cells. Mutant HIV-1 without Vpu (&#x00394;Vpu virus) grows poorly relative to wild-type virus. Recently, a cellular protein named Tetherin (also called BST-2) has been identified as a restriction factor against HIV-1 and is antagonized by Vpu (<xref ref-type="bibr" rid="B23">Neil et al., 2008</xref>; <xref ref-type="bibr" rid="B41">Van Damme et al., 2008</xref>). Vpu down-regulates the Tetherin from cell surface, and thereby promotes extracellular production of progeny virions (<xref ref-type="bibr" rid="B21">Malim and Emerman, 2008</xref>; <xref ref-type="bibr" rid="B1">Arias et al., 2011</xref>; <xref ref-type="bibr" rid="B28">Sato et al., 2012</xref>). The baseline mechanism for this action of Vpu is well studied as shown in <bold>Figure <xref ref-type="fig" rid="F4">4</xref></bold>. Here, it must be attentive that the anti-Tetherin activity of Vpu is host species-specific as observed for Vif. HIV-1 Vpu acts against human but not (or poorly) macaque Tetherins (<xref ref-type="bibr" rid="B29">Sauter et al., 2009</xref>, <xref ref-type="bibr" rid="B30">2010</xref>). Although the biological effect of Vpu is much milder than that of Vif as judged by the growth kinetics of mutant viruses (<bold>Figure <xref ref-type="fig" rid="F2">2</xref></bold>), Vpu may be critical for interspecies transmission through mutation/adaptation/recombinations (<xref ref-type="bibr" rid="B17">Kirchhoff, 2009</xref>; <xref ref-type="bibr" rid="B29">Sauter et al., 2009</xref>, <xref ref-type="bibr" rid="B30">2010</xref>; <xref ref-type="bibr" rid="B31">Sharp and Hahn, 2011</xref>). Thus, Vpu and Tetherin affect the HIV-1 species tropism, but the effect may be relatively small.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption><p><bold>HIV-1 replication and Tetherin.</bold> On the basis of results reported so far, the action mechanism of Vpu is depicted. Replication process for wild-type (WT) and &#x00394;Vpu mutant viruses are schematically shown on the basis of previously reported review articles (<xref ref-type="bibr" rid="B39">Tokarev et al., 2009</xref>; <xref ref-type="bibr" rid="B5">Douglas et al., 2010</xref>; <xref ref-type="bibr" rid="B6">Evans et al., 2010</xref>). TGN, trans-Golgi network.</p></caption>
<graphic xlink:href="fmicb-03-00267-g004.tif"/>
</fig>
<p>In sum, Vif and Vpu counteract the major restriction factors APOBEC3 proteins and Tetherin/BST-2, respectively, and represent viral determinants for the host range of HIV-1 (<bold>Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref></bold>). It is intriguing to note that these factors would have shaped HIV-1 and made it unique among various primate immunodeficiency viruses (<bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold>).</p>
</sec>
<sec>
<title>Vpx AND Vpr PROTEINS</title>
<p>Vpx and Vpr proteins are necessary for efficient viral replication (<xref ref-type="bibr" rid="B21">Malim and Emerman, 2008</xref>; <xref ref-type="bibr" rid="B8">Fujita et al., 2010</xref>). In macrophages, &#x00394;Vpx replication is not detectable and this defect has been shown to be present at post-entry and before/during the reverse transcription process (<xref ref-type="bibr" rid="B7">Fujita et al., 2008</xref>, <xref ref-type="bibr" rid="B8">2010</xref>; <xref ref-type="bibr" rid="B36">Srivastava et al., 2008</xref>). Also in some lymphocyte cell lines and in primary lymphocytes, Vpx protein is critical for viral replication (<xref ref-type="bibr" rid="B40">Ueno et al., 2003</xref>; <xref ref-type="bibr" rid="B8">Fujita et al., 2010</xref>; <xref ref-type="bibr" rid="B3">Doi et al., 2011</xref>). Because &#x00394;Vpr virus is somewhat replication-defective in some cells (for both HIV-1 and HIV-2), it is not unreasonable to assume that Vpr may play a role in the viral growth cycle. As such, Vpx and Vpr are important for <italic>in vivo</italic> viral replication and finally for viral pathogenicity (<xref ref-type="bibr" rid="B8">Fujita et al., 2010</xref>).</p>
<p>Very recently, SAMHD1 and APOBEC3A have been reported to be myeloid cell-specific restriction factors against HIV-1 counteracted by Vpx (<xref ref-type="bibr" rid="B2">Berger et al., 2011</xref>; <xref ref-type="bibr" rid="B12">Hrecka et al., 2011</xref>; <xref ref-type="bibr" rid="B20">Laguette et al., 2011</xref>). Whether these proteins are associated with the HIV-1 species tropism described in this review article, and whether they can explain the <italic>in vitro</italic> and <italic>in vivo</italic> situation of HIV-2/SIVmac mutant viruses mentioned above remain to be determined (<xref ref-type="bibr" rid="B8">Fujita et al., 2010</xref>; <xref ref-type="bibr" rid="B25">Nomaguchi et al., 2011</xref>).</p>
</sec>
<sec>
<title>CONCLUSION</title>
<p>In this review, we have described the major determinants for the species tropism of HIV-1. Structural Gag-CA and accessory Vif and Vpu proteins are clearly involved in this host range of HIV-1 as viral factors (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>). Cellular proteins that interact with these and contribute to this tropism are definitely the restriction factors (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>). In total, interplays between the viral and cellular responsible factors decide this unique and limited tropism of HIV-1. Whether there are the other factors that affect the HIV-1 species tropism is awaiting further investigations. In this regard, the biology of Vpx deserves attention. Because Vpx is present in SIVmac but not in HIV-1 (<bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold>), it may inactivate a cellular anti-viral protein(s) which is not recognized by HIV-1 proteins.</p>
<p>In both basic and applicable points of view, the narrow host range of HIV-1 is burdensome obstacle to overcome. Assuming that HIV-1mt can grow and cause disease similarly with SIVmac in macaques, we would be able to better perform model studies to precisely analyze viral replication and pathogenicity <italic>in vivo</italic>, and to establish the effective anti-HIV-1/AIDS strategies. To the best of our knowledge, there are no such HIV-1mt clones so far (<xref ref-type="bibr" rid="B10">Hatziioannou et al., 2006</xref>, <xref ref-type="bibr" rid="B9">2009</xref>; <xref ref-type="bibr" rid="B15">Kamada et al., 2006</xref>; <xref ref-type="bibr" rid="B14">Igarashi et al., 2007</xref>; <xref ref-type="bibr" rid="B19">Kuroishi et al., 2009</xref>; <xref ref-type="bibr" rid="B26">Saito et al., 2011</xref>; <xref ref-type="bibr" rid="B38">Thippeshappa et al., 2011</xref>). We may further improve the ability of HIV-1mt by today&#x02019;s powerful methodology if we knew all the cellular determinants for the species tropism of HIV-1. Studies in this direction are in progress in our laboratory.</p>
</sec>
<sec>
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>We thank Ms Kazuko Yoshida for excellent editorial assistance. This work was supported by a grant from the Ministry of Health, Labour and Welfare of Japan (Research on HIV/AIDS project no. H22-003).</p>
</ack>
<ref-list>
<title>REFERENCES</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arias</surname> <given-names>J. F.</given-names></name> <name><surname>Iwabu</surname> <given-names>Y.</given-names></name> <name><surname>Tokunaga</surname> <given-names>K.</given-names></name></person-group> (<year>2011</year>). <article-title>Structural basis for the antiviral activity of BST-2/tetherin and its viral antagonism.</article-title> <source><italic>Front. Microbiol.</italic></source> <volume>2</volume>:<issue>250.</issue> <pub-id pub-id-type="doi"> 10.3389/fmicb.2011.00250</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname> <given-names>G.</given-names></name> <name><surname>Durand</surname> <given-names>S.</given-names></name> <name><surname>Fargier</surname> <given-names>G.</given-names></name> <name><surname>Nguyen</surname> <given-names>X.-N.</given-names></name> <name><surname>Cordeil</surname> <given-names>S.</given-names></name> <name><surname>Bouaziz</surname> <given-names>S.</given-names></name> <name><surname>Muriaux</surname> <given-names>D.</given-names></name> <name><surname>Darlix</surname> <given-names>J.-L.</given-names></name> <name><surname>Cimarelli</surname> <given-names>A.</given-names></name></person-group> (<year>2011</year>). <article-title>APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.</article-title> <source><italic>PLoS Pathog.</italic></source> <volume>7</volume> <issue>e1002221</issue> <pub-id pub-id-type="doi">10.1371/journal.ppat.1002221</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"> <name><surname>Doi</surname> <given-names>N.</given-names></name> <name><surname>Fujiwara</surname> <given-names>S.</given-names></name> <name><surname>Adachi</surname> <given-names>A.</given-names></name> <name><surname>Nomaguchi</surname> <given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>Rhesus M1.3S cells suitable for biological evaluation of macaque-tropic HIV/SIV clones.</article-title> <source><italic>Front. Microbiol.</italic></source> <volume>2</volume>:<issue>115.</issue> <pub-id pub-id-type="doi">10.3389/fmicb.2011.00115</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorfman</surname> <given-names>T.</given-names></name> <name><surname>Gottlinger</surname> <given-names>H. G.</given-names></name></person-group> (<year>1996</year>). <article-title>The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811.</article-title> <source><italic>J. Virol.</italic></source> <volume>70</volume> <fpage>5751</fpage>&#x02013;<lpage>5757</lpage>.</citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Douglas</surname> <given-names>J. L.</given-names></name> <name><surname>Gustin</surname> <given-names>J. K.</given-names></name> <name><surname>Viswanathan</surname> <given-names>K.</given-names></name> <name><surname>Mansouri</surname> <given-names>M.</given-names></name> <name><surname>Moses</surname> <given-names>A. V.</given-names></name> <name><surname>Fruh</surname> <given-names>K.</given-names></name></person-group> (<year>2010</year>). <article-title>The great escape: viral strategies to counter BST-2/tetherin.</article-title> <source><italic>PLoS Pathog.</italic></source> <volume>6</volume> <issue>e1000913</issue> <pub-id pub-id-type="doi">10.1371/journal.ppat.1000913</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname> <given-names>D. T.</given-names></name> <name><surname>Serra-Moreno</surname> <given-names>R.</given-names></name> <name><surname>Singh</surname> <given-names>R. K.</given-names></name> <name><surname>Guatelli</surname> <given-names>J. C.</given-names></name></person-group> (<year>2010</year>). <article-title>BST-2/tetherin: a new component of the innate immune response to enveloped viruses.</article-title> <source><italic>Trends Microbiol.</italic></source> <volume>18</volume> <fpage>388</fpage>&#x02013;<lpage>396</lpage>.</citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname> <given-names>M.</given-names></name> <name><surname>Otsuka</surname> <given-names>M.</given-names></name> <name><surname>Miyoshi</surname> <given-names>M.</given-names></name> <name><surname>Khamsri</surname> <given-names>B.</given-names></name> <name><surname>Nomaguchi</surname> <given-names>M.</given-names></name> <name><surname>Adachi</surname> <given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>Vpx is critical for reverse transcription of the human immunodeficiency virus type 2 genome in macrophages.</article-title> <source><italic>J. Virol.</italic></source> <volume>82</volume> <fpage>7752</fpage>&#x02013;<lpage>7756</lpage>.</citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname> <given-names>M.</given-names></name> <name><surname>Otsuka</surname> <given-names>M.</given-names></name> <name><surname>Nomaguchi</surname> <given-names>M.</given-names></name> <name><surname>Adachi</surname> <given-names>A.</given-names></name></person-group> (<year>2010</year>). <article-title>Multifaceted activity of HIV Vpr/Vpx proteins: the current view of their virological functions.</article-title> <source><italic>Rev. Med. Virol.</italic></source> <volume>20</volume> <fpage>68</fpage>&#x02013;<lpage>76</lpage>.</citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hatziioannou</surname> <given-names>T.</given-names></name> <name><surname>Ambrose</surname> <given-names>Z.</given-names></name> <name><surname>Chung</surname> <given-names>N. P. Y.</given-names></name><name><surname>Piatak</surname> <given-names>M.</given-names></name></person-group> Jr., <person-group person-group-type="author"><name><surname>Yuan</surname> <given-names>F.</given-names></name> <name><surname>Trubey</surname> <given-names>C. M.</given-names></name> <name><surname>Coalter</surname> <given-names>V.</given-names></name> <name><surname>Kiser</surname> <given-names>R.</given-names></name> <name><surname>Schneider</surname> <given-names>D.</given-names></name> <name><surname>Smedley</surname> <given-names>J.</given-names></name> <name><surname>Pung</surname> <given-names>R.</given-names></name> <name><surname>Gathuka</surname> <given-names>M.</given-names></name> <name><surname>Estes</surname> <given-names>J. D.</given-names></name> <name><surname>Veazey</surname> <given-names>R. S.</given-names></name> <name><surname>KewalRamani</surname> <given-names>V. N.</given-names></name> <name><surname>Lifson</surname> <given-names>J. D.</given-names></name> <name><surname>Bieniasz</surname> <given-names>P. D.</given-names></name></person-group> (<year>2009</year>). <article-title>A macaque model of HIV-1 infection.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>106</volume> <fpage>4425</fpage>&#x02013;<lpage>4429</lpage>.</citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hatziioannou</surname> <given-names>T.</given-names></name> <name><surname>Princiotta</surname> <given-names>M.</given-names></name> <name><surname>Piatak</surname> <given-names>M.</given-names> <suffix>Jr.</suffix></name> <name><surname>Yuan</surname> <given-names>F.</given-names></name> <name><surname>Zhang</surname> <given-names>F.</given-names></name> <name><surname>Lifson</surname> <given-names>J. D.</given-names></name> <name><surname>Bieniasz</surname> <given-names>P. D.</given-names></name></person-group> (<year>2006</year>). <article-title>Generation of siman-tropic HIV-1 by restriction factor evasion.</article-title> <source><italic>Science</italic></source> <volume>314</volume> <issue>95</issue>.</citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname> <given-names>R. K.</given-names></name> <name><surname>Malim</surname> <given-names>M. H.</given-names></name> <name><surname>Bishop</surname> <given-names>K. N.</given-names></name></person-group> (<year>2007</year>). <article-title>APOBEC-mediated viral restriction: not simply editing?</article-title> <source><italic>Trends Biochem. Sci.</italic></source> <volume>32</volume> <fpage>118</fpage>&#x02013;<lpage>128</lpage>.</citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hrecka</surname> <given-names>K.</given-names></name> <name><surname>Hao</surname> <given-names>C.</given-names></name> <name><surname>Gierszewska</surname> <given-names>M.</given-names></name> <name><surname>Swanson</surname> <given-names>S. K.</given-names></name> <name><surname>Kesik-Brodacka</surname> <given-names>M.</given-names></name> <name><surname>Srivastava</surname> <given-names>S.</given-names></name> <name><surname>Florens</surname> <given-names>L.</given-names></name> <name><surname>Washburn</surname> <given-names>M. P.</given-names></name> <name><surname>Skowronski</surname> <given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein.</article-title> <source><italic>Nature</italic></source> <volume>474</volume> <fpage>658</fpage>&#x02013;<lpage>661</lpage>.</citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huthoff</surname> <given-names>H.</given-names></name> <name><surname>Towers</surname> <given-names>G. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha.</article-title> <source><italic>Trends Microbiol.</italic></source> <volume>16</volume> <fpage>612</fpage>&#x02013;<lpage>619</lpage>.</citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Igarashi</surname> <given-names>T.</given-names></name> <name><surname>Iyengar</surname> <given-names>R.</given-names></name> <name><surname>Byrum</surname> <given-names>R. A.</given-names></name> <name><surname>Buckler-White</surname> <given-names>A.</given-names></name> <name><surname>Dewar</surname> <given-names>R. L.</given-names></name> <name><surname>Buckler</surname> <given-names>C. E.</given-names></name> <name><surname>Lane</surname> <given-names>H. C.</given-names></name> <name><surname>Kamada</surname> <given-names>K.</given-names></name> <name><surname>Adachi</surname> <given-names>A.</given-names></name> <name><surname>Martin</surname> <given-names>M. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Human immunodeficiency virus type 1 derivative with 7% simian immunodeficiency virus genetic content is able to establish infections in pig-tailed macaques.</article-title> <source><italic>J. Virol.</italic></source> <volume>81</volume> <fpage>11549</fpage>&#x02013;<lpage>11552</lpage>.</citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamada</surname> <given-names>K.</given-names></name> <name><surname>Igarashi</surname> <given-names>T.</given-names></name> <name><surname>Martin</surname> <given-names>M. A.</given-names></name> <name><surname>Khamsri</surname> <given-names>B.</given-names></name> <name><surname>Hatcho</surname> <given-names>K.</given-names></name> <name><surname>Yamashita</surname> <given-names>T.</given-names></name> <name><surname>Fujita</surname> <given-names>M.</given-names></name> <name><surname>Uchiyama</surname> <given-names>T.</given-names></name> <name><surname>Adachi</surname> <given-names>A.</given-names></name></person-group> (<year>2006</year>). <article-title>Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>103</volume> <fpage>16959</fpage>&#x02013;<lpage>16964</lpage>.</citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khamsri</surname> <given-names>B.</given-names></name> <name><surname>Murao</surname> <given-names>F.</given-names></name> <name><surname>Yoshida</surname> <given-names>A.</given-names></name> <name><surname>Sakurai</surname> <given-names>A.</given-names></name> <name><surname>Uchiyama</surname> <given-names>T.</given-names></name> <name><surname>Shirai</surname> <given-names>H.</given-names></name> <name><surname>Matsuo</surname> <given-names>Y.</given-names></name> <name><surname>Fujita</surname> <given-names>M.</given-names></name> <name><surname>Adachi</surname> <given-names>A.</given-names></name></person-group> (<year>2006</year>). <article-title>Comparative study on the structure and cytopathogenic activity of HIV Vpx/Vpr proteins.</article-title> <source><italic>Microbes Infect.</italic></source> <volume>8</volume> <fpage>10</fpage>&#x02013;<lpage>15</lpage>.</citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kirchhoff</surname> <given-names>F.</given-names></name></person-group> (<year>2009</year>). <article-title>Is the high virulence of HIV-1 an unfortunate coincidence of primate lentiviral evolution?</article-title> <source><italic>Nat. Rev. Microbiol.</italic></source> <volume>7</volume> <fpage>467</fpage>&#x02013;<lpage>476</lpage>.</citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kitamura</surname> <given-names>S.</given-names></name> <name><surname>Ode</surname> <given-names>H.</given-names></name> <name><surname>Iwatani</surname> <given-names>Y.</given-names></name></person-group> (<year>2011</year>). <article-title>Structual features of antiviral APOBEC3 proteins are linked to their functional activities.</article-title> <source><italic>Front. Microbiol.</italic> 2:258.</source> <pub-id pub-id-type="doi"> 10.3889/fmicb.2011.00258</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuroishi</surname> <given-names>A.</given-names></name> <name><surname>Saito</surname> <given-names>A.</given-names></name> <name><surname>Shingai</surname> <given-names>Y.</given-names></name> <name><surname>Shioda</surname> <given-names>T.</given-names></name> <name><surname>Nomaguchi</surname> <given-names>M.</given-names></name> <name><surname>Adachi</surname> <given-names>A.</given-names></name> <name><surname>Akari</surname> <given-names>H.</given-names></name> <name><surname>Nakayama</surname> <given-names>E. E.</given-names></name></person-group> (<year>2009</year>). <article-title>Modification of a loop sequensce between alpha-helices 6 and 7 of virus capsid (CA) protein in a human immunodeficiency virus type 1 (HIV-1) derivative that has simian immunodeficiency virus (SIVmac239) Vif and CA alpha-helices 4 and 5 loop improves replication in cynomolgus monkey cells.</article-title> <source><italic>Retrovirology</italic></source> <volume>6</volume> <issue>70</issue>.</citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laguette</surname> <given-names>N.</given-names></name> <name><surname>Sobhian</surname> <given-names>B.</given-names></name> <name><surname>Casartelli</surname> <given-names>N.</given-names></name> <name><surname>Ringeard</surname> <given-names>M.</given-names></name> <name><surname>Chable-Bessia</surname> <given-names>C.</given-names></name> <name><surname>Segeral</surname> <given-names>E.</given-names></name> <name><surname>Yatim</surname> <given-names>A.</given-names></name> <name><surname>Emiliani</surname> <given-names>S.</given-names></name> <name><surname>Schwartz</surname> <given-names>O.</given-names></name> <name><surname>Benkirane</surname> <given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx.</article-title> <source><italic>Nature</italic></source> <volume>474</volume> <fpage>654</fpage>&#x02013;<lpage>657</lpage>.</citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malim</surname> <given-names>M. H.</given-names></name> <name><surname>Emerman</surname> <given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>HIV-1 accessory proteins-ensuring viral survival in a hostile environment.</article-title> <source><italic>Cell Host Microbe</italic></source> <volume>3</volume> <fpage>388</fpage>&#x02013;<lpage>398</lpage>.</citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname> <given-names>E. E.</given-names></name> <name><surname>Shioda</surname> <given-names>T.</given-names></name></person-group> (<year>2012</year>). <article-title>TRIM5&#x003B1; and species tropism of HIV/SIV.</article-title> <source><italic>Front. Microbiol.</italic></source> <volume>3</volume>:<issue>13.</issue> <pub-id pub-id-type="doi">10.3389/fmicb.2012.00013</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neil</surname> <given-names>S. J.</given-names></name> <name><surname>Zang</surname> <given-names>T.</given-names></name> <name><surname>Bieniasz</surname> <given-names>P. D.</given-names></name></person-group> (<year>2008</year>). <article-title>Tether ininhibits retrovirus release and is antagonized by HIV-1 Vpu.</article-title> <source><italic>Nature</italic></source> <volume>451</volume> <fpage>425</fpage>&#x02013;<lpage>430</lpage>.</citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nomaguchi</surname> <given-names>M.</given-names></name> <name><surname>Doi</surname> <given-names>N.</given-names></name> <name><surname>Kamada</surname> <given-names>K.</given-names></name> <name><surname>Adachi</surname> <given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>Species barrier of HIV-1 and its jumping by virus engineering.</article-title> <source><italic>Rev. Med. Virol.</italic></source> <volume>18</volume> <fpage>261</fpage>&#x02013;<lpage>275</lpage>.</citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nomaguchi</surname> <given-names>M.</given-names></name> <name><surname>Fujita</surname> <given-names>M.</given-names></name> <name><surname>Adachi</surname> <given-names>A.</given-names></name></person-group> (<year>2011</year>). <article-title>The fourth major restriction factor against HIV/SIV.</article-title> <source><italic>Front. Microbiol.</italic></source> <volume>2</volume>:<issue>132.</issue> <pub-id pub-id-type="doi">10.3389/fmicb.2011.00132</pub-id></citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname> <given-names>A.</given-names></name> <name><surname>Nomaguchi</surname> <given-names>M.</given-names></name> <name><surname>Iijima</surname> <given-names>S.</given-names></name> <name><surname>Kuroishi</surname> <given-names>A.</given-names></name> <name><surname>Yoshida</surname> <given-names>T.</given-names></name> <name><surname>Lee</surname> <given-names>Y. J.</given-names></name> <name><surname>Hayakawa</surname> <given-names>T.</given-names></name> <name><surname>Kono</surname> <given-names>K.</given-names></name> <name><surname>Nakayama</surname> <given-names>E. E.</given-names></name> <name><surname>Shioda</surname> <given-names>T.</given-names></name> <name><surname>Yasutomi</surname> <given-names>Y.</given-names></name> <name><surname>Adachi</surname> <given-names>A.</given-names></name> <name><surname>Matano</surname> <given-names>T.</given-names></name> <name><surname>Akari</surname> <given-names>H.</given-names></name></person-group> (<year>2011</year>). <article-title>Improved capacity of a monkey-tropic HIV-1 derivative to replicate in cynomolgus monkeys with minimal modifications.</article-title> <source><italic>Microbes Infect.</italic></source> <volume>13</volume> <fpage>58</fpage>&#x02013;<lpage>64</lpage>.</citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakuma</surname> <given-names>R.</given-names></name> <name><surname>Takeuchi</surname> <given-names>H.</given-names></name></person-group> (<year>2012</year>). <article-title>SIV replication in human cells.</article-title> <source><italic>Front. Microbiol.</italic></source> <volume>3</volume>:<issue>162.</issue> <pub-id pub-id-type="doi">10.3389/fmicb.2012.00162</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname> <given-names>K.</given-names></name> <name><surname>Gee</surname> <given-names>P.</given-names></name> <name><surname>Koyanagi</surname> <given-names>Y.</given-names></name></person-group> (<year>2012</year>). <article-title>Vpu and BST-2: still not there yet?</article-title> <source><italic>Front. Microbiol.</italic></source> <volume>3</volume>:<issue>131.</issue> <pub-id pub-id-type="doi">10.3389/fmicb.2012.00131</pub-id></citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sauter</surname> <given-names>D.</given-names></name> <name><surname>Schindler</surname> <given-names>M.</given-names></name> <name><surname>Specht</surname> <given-names>A.</given-names></name> <name><surname>Landford</surname> <given-names>W. N.</given-names></name> <name><surname>Munch</surname> <given-names>J.</given-names></name> <name><surname>Kim</surname> <given-names>K.-A.</given-names></name> <name><surname>Votteler</surname> <given-names>J.</given-names></name> <name><surname>Schubert</surname> <given-names>U.</given-names></name> <name><surname>Bibollet-Ruche</surname> <given-names>F.</given-names></name> <name><surname>Keele</surname> <given-names>B. R. F.</given-names></name><name><surname>Takehisa</surname> <given-names>J.</given-names></name> <name><surname>Ogando</surname> <given-names>Y.</given-names></name> <name><surname>Ochsenbauer</surname> <given-names>C.</given-names></name> <name><surname>Kappes</surname> <given-names>J. C.</given-names></name> <name><surname>Ayouba</surname> <given-names>A.</given-names></name> <name><surname>Peeters</surname> <given-names>M.</given-names></name> <name><surname>Learn</surname> <given-names>G. H.</given-names></name> <name><surname>Shaw</surname> <given-names>G.</given-names></name> <name><surname>Sharp</surname> <given-names>P. M.</given-names></name> <name><surname>Bieniasz</surname> <given-names>P.</given-names></name> <name><surname>Hahn</surname> <given-names>B. H.</given-names></name> <name><surname>Hatziioannou</surname> <given-names>T.</given-names></name> <name><surname>Kirchhoff</surname> <given-names>F.</given-names></name></person-group> (<year>2009</year>). <article-title>Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains.</article-title> <source><italic>Cell Host Microbe</italic></source> <volume>6</volume> <fpage>409</fpage>&#x02013;<lpage>421</lpage>.</citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sauter</surname> <given-names>D.</given-names></name> <name><surname>Specht</surname> <given-names>A.</given-names></name> <name><surname>Kirchhoff</surname> <given-names>F.</given-names></name></person-group> (<year>2010</year>). <article-title>Tetherin: holding on and letting go.</article-title> <source><italic>Cell</italic></source> <volume>141</volume> <fpage>392</fpage>&#x02013;<lpage>398</lpage>.</citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"> <name><surname>Sharp</surname> <given-names>P. M.</given-names></name> <name><surname>Hahn</surname> <given-names>B. H.</given-names></name></person-group> (<year>2011</year>). <article-title>Origins of HIV and the AIDS pandemic.</article-title> <source><italic>Cold Spring Harb. Perspect. Med.</italic></source> <volume>1</volume> <issue>a006841</issue>.</citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sheehy</surname> <given-names>A. M.</given-names></name> <name><surname>Gaddis</surname> <given-names>N. C.</given-names></name> <name><surname>Choi</surname> <given-names>J. D.</given-names></name> <name><surname>Malim</surname> <given-names>M. H.</given-names></name></person-group> (<year>2002</year>). <article-title>Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.</article-title> <source><italic>Nature</italic></source> <volume>418</volume> <fpage>646</fpage>&#x02013;<lpage>650</lpage>.</citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname> <given-names>R.</given-names></name> <name><surname>Adachi</surname> <given-names>A.</given-names></name></person-group> (<year>1992</year>). <article-title>SIV/HIV recombinants and their use in studying biological properties.</article-title> <source><italic>AIDS Res. Hum. Retroviruses</italic></source> <volume>8</volume> <fpage>403</fpage>&#x02013;<lpage>409</lpage>.</citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname> <given-names>R.</given-names></name> <name><surname>Kawamura</surname> <given-names>M.</given-names></name> <name><surname>Sakai</surname> <given-names>H.</given-names></name> <name><surname>Hayami</surname> <given-names>M.</given-names></name> <name><surname>Ishimoto</surname> <given-names>A.</given-names></name> <name><surname>Adachi</surname> <given-names>A.</given-names></name></person-group> (<year>1991</year>). <article-title>Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells.</article-title> <source><italic>J. Virol.</italic></source> <volume>65</volume> <fpage>3514</fpage>&#x02013;<lpage>3520</lpage>.</citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname> <given-names>R.</given-names></name> <name><surname>Sakai</surname> <given-names>H.</given-names></name> <name><surname>Kawamura</surname> <given-names>M.</given-names></name> <name><surname>Tokunaga</surname> <given-names>K.</given-names></name> <name><surname>Adachi</surname> <given-names>A.</given-names></name></person-group> (<year>1995</year>). <article-title>Early replication block of human immunodeficiency type 1 in monkey cells.</article-title> <source><italic>J. Gen. Virol.</italic></source> <volume>76</volume> <fpage>2723</fpage>&#x02013;<lpage>2730</lpage>.</citation></ref>
<ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname> <given-names>S.</given-names></name> <name><surname>Swanson</surname> <given-names>S. K.</given-names></name> <name><surname>Manel</surname> <given-names>N.</given-names></name> <name><surname>Florens</surname> <given-names>L.</given-names></name> <name><surname>Washburn</surname> <given-names>M. P.</given-names></name> <name><surname>Skowronski</surname> <given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable to enhance macrophage infection.</article-title> <source><italic>PLoS Pathog.</italic></source> <volume>4</volume> <issue>e1000059</issue> <pub-id pub-id-type="doi"> 10.1371/journal.ppat.1000059</pub-id></citation></ref>
<ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strebel</surname> <given-names>K.</given-names></name> <name><surname>Luban</surname> <given-names>J.</given-names></name> <name><surname>Jeang</surname> <given-names>K. T.</given-names></name></person-group> (<year>2009</year>). <article-title>Human cellular restriction factors that target HIV-1 replication.</article-title> <source><italic>BMC Med.</italic></source> <volume>7</volume> <issue>48</issue> <pub-id pub-id-type="doi"> 10.1186/1741-7015-7-48</pub-id></citation></ref>
<ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thippeshappa</surname> <given-names>R.</given-names></name> <name><surname>Polacino</surname> <given-names>P.</given-names></name> <name><surname>Kimata</surname> <given-names>M. T. Y.</given-names></name><name><surname>Siwak</surname> <given-names>E. B.</given-names></name> <name><surname>Anderson</surname> <given-names>D.</given-names></name> <name><surname>Wang</surname> <given-names>W.</given-names></name> <name><surname>Sherwood</surname> <given-names>L.</given-names></name> <name><surname>Arora</surname> <given-names>R.</given-names></name> <name><surname>Wen</surname> <given-names>M.</given-names></name> <name><surname>Zhou</surname> <given-names>P.</given-names></name> <name><surname>Hu</surname> <given-names>S.-L.</given-names></name> <name><surname>Kimata</surname> <given-names>J. T.</given-names></name></person-group> (<year>2011</year>). <article-title>Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1.</article-title> <source><italic>J. Virol.</italic></source> <volume>85</volume> <fpage>3767</fpage>&#x02013;<lpage>3779</lpage>.</citation></ref>
<ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tokarev</surname> <given-names>A.</given-names></name> <name><surname>Skasko</surname> <given-names>M.</given-names></name> <name><surname>Fitzpatrick</surname> <given-names>K.</given-names></name> <name><surname>Guatelli</surname> <given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.</article-title> <source><italic>AIDS Res. Hum. Retroviruses</italic></source> <volume>25</volume> <fpage>1197</fpage>&#x02013;<lpage>1210</lpage>.</citation></ref>
<ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueno</surname> <given-names>F.</given-names></name> <name><surname>Shiota</surname> <given-names>H.</given-names></name> <name><surname>Miyaura</surname> <given-names>M.</given-names></name> <name><surname>Yoshida</surname> <given-names>A.</given-names></name> <name><surname>Sakurai</surname> <given-names>A.</given-names></name> <name><surname>Tatsuki</surname> <given-names>J.</given-names></name> <name><surname>Koyama</surname> <given-names>A. H.</given-names></name> <name><surname>Akari</surname> <given-names>H.</given-names></name> <name><surname>Adachi</surname> <given-names>A.</given-names></name> <name><surname>Fujita</surname> <given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>Vpx and Vpr proteins up-regulate the viral infectivity by a distinct mechanism in lymphocytic cells.</article-title> <source><italic>Microbes Infect.</italic></source> <volume>5</volume> <fpage>387</fpage>&#x02013;<lpage>395</lpage>.</citation></ref>
<ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Damme</surname> <given-names>N.</given-names></name> <name><surname>Goff</surname> <given-names>D.</given-names></name> <name><surname>Katsura</surname> <given-names>C.</given-names></name> <name><surname>Jorgenson</surname> <given-names>R. L.</given-names></name> <name><surname>Mitchell</surname> <given-names>R.</given-names></name> <name><surname>Johnson</surname> <given-names>M. C.</given-names></name> <name><surname>Stephens</surname> <given-names>E. B.</given-names></name> <name><surname>Guatelli</surname> <given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the Vpu protein.</article-title> <source><italic>Cell Host Microbe</italic></source> <volume>3</volume> <fpage>245</fpage>&#x02013;<lpage>252</lpage>.</citation></ref>
</ref-list>
</back>
</article>